Search by product name, CAS, target or catalog number. Press Down Arrow to reach product suggestions, Tab to move between links, and Escape to close suggestions.
NOD-like receptor (NLR) inhibitors and activators target cytosolic sensors of microbial and cellular danger signals. These receptors carry a nucleotide-binding oligomerization domain (NOD) and include NOD1, NOD2 and the NLR family pyrin domain-containing (NLRP) proteins. In 2001, a frameshift mutation in NOD2 was associated with susceptibility to Crohn's disease. Some NLRs, such as NLRP3, assemble inflammasomes, protein platforms that activate inflammatory caspases and process pro-interleukin-1β. MCC950 sodium was reported in 2015 as a selective small-molecule inhibitor of the NLRP3 inflammasome, whereas the ionophore nigericin sodium salt activates it. Mifamurtide, a synthetic muramyl dipeptide analog, acts on NOD2, and NOD-IN-1 inhibits NOD1 and NOD2.
NLRP3 Agonist 1 is a potent agonist targeting the NLRP3 inflammasome. This compound has been shown to activate Caspase-1, leading to the cleavage of pro-inflammatory cytokines pro-IL-1β and pro-IL-18 into their active forms. NLRP3 Agonist 1 can be utilized in research focused on inflammation and immune response pathways.
FP-20 sodium is a selective agonist of Toll-like receptor 4 (TLR4) that serves as a potent vaccine adjuvant. It activates the MAPK pathway and promotes NLRP3-dependent inflammasome activation, enhancing immune responses. In mouse vaccination studies using ovalbumin (OVA) antigen, FP-20 sodium demonstrated no toxicity while effectively inducing IgG production, making it a valuable tool for immunological research.
Out of stock
All 3 sizes
BMS-986299 is a first-in-class NLRP3 inflammasome agonist that exhibits potent activation with an EC50 of 1.28 μM. This compound is valuable for research exploring the role of NLRP3 in inflammatory processes and immune responses. Its ability to selectively stimulate the NLRP3 pathway makes it an important tool for studies related to autoinflammatory diseases and the development of novel immunotherapeutic strategies.
Synonyms: 2GBI
2-Guanidinobezimidazole is a selective agonist of the NLRP3 inflammasome, exhibiting a KD value of 1.29 μM towards His-GFP-NLRP3. By binding directly to the leucine-rich repeat (LRR) domain of NLRP3, it facilitates inflammasome assembly and activation. This compound is pertinent for research into anti-tumor immunity, demonstrating potential to inhibit tumor growth and address resistance to immune checkpoint blockade (ICB).
UNC9995 is a β-arrestin2-biased agonist of the dopamine receptor Drd2. This compound inhibits NLRP3 inflammasome activation by promoting the interaction between β-arrestin2 and NLRP3, thereby preventing neuronal degeneration. Furthermore, UNC9995 activates Drd2/β-arrestin2 signaling, which mitigates the transcription of inflammation-related genes induced by the JAK/STAT3 pathway. Research shows that UNC9995 enhances depressive behavior in mouse models and improves astrocyte dysfunctions, making it a valuable tool for studying neuroinflammatory processes and mood disorders.
O-1602 is a potent agonist of GPR55, a G protein-coupled receptor involved in various neuroinflammatory processes. It has been shown to reduce both the number and activation of hippocampal microglia triggered by methamphetamine exposure. Additionally, O-1602 decreases the expression of key proteins associated with the NLRP3 inflammasome, including NLRP3, ASC, and Caspase-1, making it a valuable tool for studies related to neuroinflammation and neurodegenerative disease research.
NPBA is a potassium K2P channel TASK-3 (KCNK9) agonist and TWIK2 (KCNK1) channel blocker. This compound plays a crucial role in inhibiting NLRP3 inflammasome activation in macrophages, making it valuable for research into inflammatory pathways and potassium channel function. Its unique mechanism provides insights into potential therapeutic applications in inflammatory diseases.
